BOLDEN THERAPEUTICS, INC.

Providence, RI · Biotech · Private

Antisense oligonucleotide (ASO) therapeutics targeting Adult Hippocampal Neurogenesis pathway to treat Alzheimer's disease

Grants
$2.7M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Promoting adult hippocampal neurogenesis in Alzheimer's Disease using an antibody-based therapy$896,914
Federal grantDepartment of Health and Human Services · Phase I · Promoting adult hippocampal neurogenesis using antisense oligonucleotides as an Alzheimer's disease therapy$497,550
Federal grantDepartment of Health and Human Services · Phase I · Entrepreneurial development award for a novel Alzheimer's disease therapeutic$406,466
Federal grantDepartment of Health and Human Services · Phase I · Promoting adult hippocampal neurogenesis in Alzheimer's Disease using an antibody-based therapy$396,914
Federal grantDepartment of Health and Human Services · Phase I · Preclinical characterization of splice-modifying antisense oligonucleotides targeting neurogenesis in human AD neural cells$504,505
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2975INVVAX, INC.——
2976CAMBIUM ONCOLOGY LLC——
2977MEDICATIONS DISCOVERY TEXAS, INC.——
2978BOLDEN THERAPEUTICS, INC.——
2979Navire Pharma——
2980POW GENETIC SOLUTIONS, INC.——
2981QUORUM INNOVATIONS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Musk-targeting Oligonucleotidesapplication
  • Musk-targeting Oligonucleotidesapplication
  • Musk-targeting Oligonucleotidesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.